ARS Pharmaceuticals Faces Securities Fraud Lawsuit; Investors Have October 5 Deadline
Rosen Law Firm is notifying purchasers of ARS Pharmaceuticals securities of an opportunity to seek compensation in a securities fraud lawsuit. The deadline to serve as lead plaintiff is October 5, 2026.
The Rosen Law Firm is reminding investors who purchased securities in ARS Pharmaceuticals, Inc. between March 9, 2026, and June 24, 2026, that they may be entitled to compensation without out-of-pocket fees.
The lawsuit alleges that ARS Pharmaceuticals provided investors with material information concerning the expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, through CVS Caremark. According to the complaint, the company expressed confidence that this coverage would begin on July 1, 2026, while allegedly disseminating false and misleading statements or concealing material adverse facts.
This conduct allegedly caused shareholders to purchase ARS Pharmaceuticals securities at artificially inflated prices. When the true details emerged, investors reportedly suffered damages. The Rosen Law Firm is encouraging eligible investors to contact them by the October 5, 2026 deadline to join the class action and potentially serve as lead plaintiff.
The firm, which specializes in securities class actions and shareholder derivative litigation, has recovered billions of dollars for investors in previous cases. Investors considering joining the lawsuit are advised to select qualified counsel with a track record of success.